Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
Cardiovascular Drugs and Therapy · 2025-12 · 39 (6) · 1331-1341
DOI: 10.1007/s10557-024-07613-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 12.09.2024. Verfasst von Michael Nakhla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA. Michael.Nakhla@StVincentHospital.com. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Suicide, Alopecia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: With the increasing popularity of glucagon-like peptide 1 receptor agonists (GLP1-RAs), numerous safety concerns arose pertaining to suicide, hair loss, and aspiration risks. We attempted to validate these concerns. METHODS: We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency's (EudraVigilance), and the World Health Organization-Vigibase. OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin. The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ2). A positive signal was detected if PRR > 2 and χ2 > 4 for any drug-event pair. RESULTS: No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks. Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is. GLP1-RAs were the most reported class with hair loss [ROR = 0.61 (0.60-0.64)], and semaglutide, liraglutide, and dulaglutide were the three leading medications. GLP1-RAs ranked lower with aspiration events, which were led by sitagliptin and DPP4is as a group. CONCLUSION: GLP1-RAs exhibit higher reporting of suicide, hair loss, and aspiration events when compared to several other antidiabetic medications despite not meeting the criteria for positive signals yet. This warrants intensive monitoring and reporting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA. Michael.Nakhla@StVincentHospital.com.
- Department of Internal Medicine, Ocean University Medical Center, Brick, NJ, USA.
- Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA.
ORCID-Profile: Michael Nakhla
Zitieren
APA
Nakhla, M., Nair, A., Balani, P., Ujjawal, A., Arun Kumar, P., Dasari, M., Yukselen, Z., Bansal, K., Ganatra, S., & Dani, S. S. (2025). Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study. Cardiovascular Drugs and Therapy, 39(6), 1331-1341. https://doi.org/10.1007/s10557-024-07613-w
Vancouver
Nakhla M, Nair A, Balani P, Ujjawal A, Arun Kumar P, Dasari M, et al. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study. Cardiovascular Drugs and Therapy. 2025;39(6):1331-1341. doi:10.1007/s10557-024-07613-w
BibTeX
@article{Nakhla2025,
author = {Nakhla, Michael and Nair, Ambica and Balani, Prachi and Ujjawal, Aditi and Arun Kumar, Pramukh and Dasari, Mahati and Yukselen, Zeynep and Bansal, Kannu and Ganatra, Sarju and Dani, Sourbha S},
title = {Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
volume = {39},
number = {6},
pages = {1331--1341},
doi = {10.1007/s10557-024-07613-w}
}
EUVIMED